Moderna and merck announce mrna-4157 (v940) in combination with keytruda(r) (pembrolizumab) demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus keytruda at three years
At a median planned follow-up of approximately three years, mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 49% (hr=0.510 [95% ci, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (hr=0.384 [95% ci, 0.172-0.858]; one-sided nominal p= 0.0077) compared to keytruda alone in stage iii/iv melanoma patients with high risk of recurrence following complete resection data builds on the primary analysis reported at aacr and asco in 2023, which showed that mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 44% and reduced the risk of distant metastasis or death by 65% at a median planned follow-up of approximately two years companies have initiated phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types cambridge, ma and rahway, nj / accesswire / december 14, 2023/ moderna, inc. (nasdaq:mrna) and merck (nyse:mrk), known as msd outside of the united states and canada, today announced follow-up data from the phase 2b randomized keynote-942/mrna-4157-p201 study, a clinical trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv) following complete resection. in this planned analysis occurring with a median follow-up of approximately three years, adjuvant treatment with mrna-4157 (v940) in combination with keytruda continued to demonstrate a clinically meaningful improvement in recurrence-free survival (rfs), reducing the risk of recurrence or death by 49% (hr=0.510 [95% ci, 0.288-0.906]; one-sided nominal p=0.0095) compared with keytruda alone.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission